Bristol-Myers Acquires ZymoGenetics

Image via Wikipedia Healthcare Sector Breaking News for Tuesday, September 07, 2010

Bristol-Myers Squib to merge with ZymoGenetics

After the bell Tuesday, Bristol-Myers Squibb Company (NYSE:BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that the companies have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash.

Last Week's Top Performers for the BioPharma Market

I was almost too distaught to write an article after last Friday but decided we have to move on and look for gems in the rough. So there were a few Gems but a lot of Glooms. BioPharma Indexes are down almost 5 percent based on last weeks momentum downslide in the overall market. For just a taste of how bad it was ProShares UltraShort S&;P500 (ETF) (NYSE:SDS) was up 7.4% on shorting the market.

But lets take a look at some Top Performances last week.